219 related articles for article (PubMed ID: 35736346)
1. Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
Andrieu C; McNamee N; Larkin AM; Maguire A; Menon R; Mueller-Eisert J; Horgan N; Kennedy S; Gullo G; Crown J; Walsh N
Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736346
[TBL] [Abstract][Full Text] [Related]
2. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
6. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
[TBL] [Abstract][Full Text] [Related]
7. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
8. Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.
Patterson A; Auslander N
Nat Commun; 2022 Sep; 13(1):5151. PubMed ID: 36123351
[TBL] [Abstract][Full Text] [Related]
9. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
[TBL] [Abstract][Full Text] [Related]
10. Incidence of New Primary Cutaneous Melanoma in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: A Single-Center Cohort Study.
Nanda JK; Dusza SW; Navarrete-Dechent C; Liopyris K; Marghoob AA; Marchetti MA
JAMA Dermatol; 2021 Jan; 157(1):79-83. PubMed ID: 32936222
[TBL] [Abstract][Full Text] [Related]
11. Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
Shi F; Zhang W; Yang Y; Yang Y; Zhao J; Xie M; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():721409. PubMed ID: 34795662
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-based therapy for advanced acral and mucosal melanoma.
Mori T; Izumi T; Doi R; Kamimura A; Takai S; Teramoto Y; Nakamura Y
Exp Dermatol; 2023 Mar; 32(3):276-289. PubMed ID: 36477933
[TBL] [Abstract][Full Text] [Related]
13. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
14. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
15. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy.
Vilbert M; Koch EC; Rose AAN; Laister RC; Gray D; Sotov V; Penny S; Spreafico A; Pinto DM; Butler MO; Saibil SD
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509369
[TBL] [Abstract][Full Text] [Related]
17. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
18. Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.
Dennis MJ; Bylsma S; Madlensky L; Pagadala MS; Carter H; Patel SP
Front Immunol; 2024; 15():1322187. PubMed ID: 38348036
[TBL] [Abstract][Full Text] [Related]
19. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Coleman S; Xie M; Tarhini AA; Tan AC
Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
[TBL] [Abstract][Full Text] [Related]
20. DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation.
Yan J; Wang S; Zhang J; Yuan Q; Gao X; Zhang N; Pan Y; Zhang H; Liu K; Yu J; Lu L; Liu H; Gao X; Zhao S; Zhang W; Reyila A; Qi Y; Zhang Q; Cang S; Lu Y; Pan Y; Kong Y; Nie Y
Cancer Biol Med; 2023 Dec; 21(3):252-66. PubMed ID: 38164720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
